Cargando…

Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis

OBJECTIVES: The cytokine oncostatin M (OSM) is implicated in the pathology of SSc. Inhibiting OSM signalling using GSK2330811 (an anti-OSM monoclonal antibody) in patients with SSc has the potential to slow or stop the disease process. METHODS: This multicentre, randomized, double-blind, placebo-con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denton, Christopher P, del Galdo, Francesco, Khanna, Dinesh, Vonk, Madelon C, Chung, Lorinda, Johnson, Sindhu R, Varga, John, Furst, Daniel E, Temple, Jane, Zecchin, Chiara, Csomor, Eszter, Lee, Amy, Wisniacki, Nicolas, Flint, Shaun M, Reid, Juliet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788816/ https://www.ncbi.nlm.nih.gov/pubmed/35583273 http://dx.doi.org/10.1093/rheumatology/keac300

Ejemplares similares

In vivo affinity and target engagement in skin and blood in a first‐time‐in‐human study of an anti‐oncostatin M monoclonal antibody
por: Reid, Juliet, et al.
Publicado: (2018)

Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study
por: Clark, Kristina E N, et al.
Publicado: (2022)

The role of the oncostatin M/OSM receptor β axis in activating dermal microvascular endothelial cells in systemic sclerosis
por: Marden, G., et al.
Publicado: (2020)

Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716
por: RICHARDS, Carl D., et al.
Publicado: (2020)

Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit
por: Kakkar, Vishal, et al.
Publicado: (2022)

Is there still a role for cyclophosphamide in the treatment of systemic sclerosis?
por: Vonk, Madelon C
Publicado: (2020)

Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
por: Khanna, Dinesh, et al.
Publicado: (2020)

Multifaceted oncostatin M: novel roles and therapeutic potential of the oncostatin M signaling in rheumatoid arthritis
por: Han, Liang, et al.
Publicado: (2023)

Systemic sclerosis in the time of COVID-19
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2022)

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
por: Coghlan, J Gerry, et al.
Publicado: (2014)

Oncostatin M Modulation of Lipid Storage
por: Elks, Carrie M., et al.
Publicado: (2015)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review
por: Ross, Laura, et al.
Publicado: (2023)

The Enigmatic Cytokine Oncostatin M and Roles in Disease
por: Richards, Carl D.
Publicado: (2013)

Oncostatin M promotes lipolysis in white adipocytes
por: van Krieken, Pim P., et al.
Publicado: (2022)

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study
por: Visovatti, Scott H, et al.
Publicado: (2014)

Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis
por: Domsic, Robyn T., et al.
Publicado: (2023)

Oncostatin M was associated with thrombosis in patients with atrial fibrillation
por: Xie, Jun, et al.
Publicado: (2017)

Oncostatin M, an Underestimated Player in the Central Nervous System
por: Houben, Evelien, et al.
Publicado: (2019)

Role of oncostatin-M in ECM remodeling and plaque vulnerability
por: Patel, Parth, et al.
Publicado: (2023)

Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets
por: Nevskaya, Tatiana, et al.
Publicado: (2021)

WNT16 is Robustly Increased by Oncostatin M in Mouse Calvarial Osteoblasts and Acts as a Negative Feedback Regulator of Osteoclast Formation Induced by Oncostatin M
por: Henning, Petra, et al.
Publicado: (2021)

A receptor fusion protein for the inhibition of murine oncostatin M
por: Brolund, Liv, et al.
Publicado: (2011)

The role of oncostatin M receptor gene polymorphisms in bladder cancer
por: Deng, Shi, et al.
Publicado: (2019)

Expression of Oncostatin M in Early Gastric Cancer and Precancerous Lesions
por: Shi, Jihua, et al.
Publicado: (2019)

Adipocyte Oncostatin Receptor Regulates Adipose Tissue Homeostasis and Inflammation
por: Sanchez-Infantes, David, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials
por: Choy, Ernest H, et al.
Publicado: (2013)

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
por: Khanna, Dinesh, et al.
Publicado: (2018)

Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease
por: Khanna, Dinesh, et al.
Publicado: (2019)

Feasibility of online home spirometry in systemic sclerosis–associated interstitial lung disease: a pilot study
por: Moor, Catharina C, et al.
Publicado: (2020)

Synergistic interactions of proinflammatory cytokines with oncostatin M: implications for joint destruction
por: Cawston, T, et al.
Publicado: (2003)

Regulation of IL-33 by Oncostatin M in Mouse Lung Epithelial Cells
por: Richards, Carl D., et al.
Publicado: (2016)

Calcium silicate bioactive ceramics induce osteogenesis through oncostatin M
por: Zhou, Panyu, et al.
Publicado: (2020)

Macrophage hypoxia signaling regulates cardiac fibrosis via Oncostatin M
por: Abe, Hajime, et al.
Publicado: (2019)

Oncostatin M in the Regulation of Connective Tissue Cells and Macrophages in Pulmonary Disease
por: Richards, Carl D., et al.
Publicado: (2019)

Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer
por: Caligiuri, Alessandra, et al.
Publicado: (2022)

Digital Ischemic Loss in Systemic Sclerosis
por: Marvi, Umaima, et al.
Publicado: (2010)

High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
por: Guo, Angela, et al.
Publicado: (2022)

Patient perception of disease burden in diffuse cutaneous systemic sclerosis
por: Khanna, Dinesh, et al.
Publicado: (2019)

Ilex rotunda Thunb Protects Against Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Restoring the Intestinal Mucosal Barrier and Modulating the Oncostatin M/Oncostatin M Receptor Pathway
por: Li, Yao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5a2l2uljvmkinec0cos08faudi